Arrayit Corporation (OTCBB:ARYC), a life sciences and molecular
diagnostics leader, announces today that the Company has sold a $129,548
NanoPrint™ LM60 Enterprise Level Microarray Printer to a leading
research laboratory in Tel Aviv, Israel. Arrayit NanoPrint™ instruments
enable microarray manufacturing in a high-throughput and highly
automated manner using advanced linear drive motion control and linear
encoders that permit nanometer positional resolution. Microarrays are
biomedical devices that contain genes, proteins, antibodies and other
molecules from the human genome and proteome printed at high-density on
glass substrates. Patient samples are labeled and reacted with
microarrays to provide answers to human health including the
pre-symptomatic detection of cancer, autoimmune disease, and other
treatable conditions.
In 2010, Arrayit received Israeli Patent Number 153848 covering
microarray methods for DNA testing, to improve the economies of scale in
genotyping by allowing thousands of patient DNA samples to be
simultaneously tested. The NanoPrint™ sale to Tel Aviv, the issued 848’
patent and other recent developments underscore Arrayit’s commitment to
providing its patented and proprietary technology to Israel in
furtherance of leading-edge life sciences research, diagnostics and an
increasingly advanced health care system. The Company is currently
seeking a joint-venture partner is Israel to further expand sales in
this important economy.
Arrayit recently announced a 51% year-over-year quarterly sales increase
in the third quarter ended September 30, 2013, with profitability and a
$1.48M net income improvement over 2012 for the first nine months of
this year. The Company also announced the appointment of renowned
biotech analyst Sid Taubenfeld to the Board of Directors, the opening of
the Company’s new corporate headquarters in Sunnyvale, California USA on
January 1, 2014, and the completion of a $1M equity capital raise with
funds to be used for Company growth and expansion.
About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray platform to
lead and empower the genetic, research, pharmaceutical, and diagnostic
communities through the discovery, development and manufacture of
proprietary life science technologies and consumables for disease
prevention, treatment and cure.
- Powerful Science for Life
Visit
http://arrayit.com/
for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as
"expect", "believe", and "should". Although we believe our expectations
are reasonable, our operations involve a number of risks and
uncertainties that are beyond our control, and these statements may turn
out not to be true. Risk factors associated with our business, including
some of the facts set forth herein, are detailed in the Company's Form
10-K for the fiscal year ended December 31, 2012 and in Form 10-Q for
the quarterly period ended September 30, 2013.
Copyright Business Wire 2013